Summary:
- The article discusses the results of a clinical trial for a new cancer treatment for patients with HER2-positive metastatic breast cancer.
- The combination of the drugs ENHERTU and pertuzumab showed a significant improvement in progression-free survival compared to the current standard treatment.
- This means the new treatment was more effective at slowing the growth and spread of the cancer, which is an important outcome for patients with this type of advanced breast cancer.